BIOMARIN PHARMACEUTICAL INC's ticker is and the CUSIP is 09061GAE1. A total of 43 filers reported holding BIOMARIN PHARMACEUTICAL INC in Q3 2017. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2018 | $4,701,000 | +110.4% | 4,573,000 | +127.2% | 0.02% | +66.7% |
| Q2 2017 | $2,234,000 | +15.0% | 2,013,000 | +17.8% | 0.02% | +7.1% |
| Q1 2017 | $1,943,000 | -22.7% | 1,709,000 | -23.4% | 0.01% | 0.0% |
| Q4 2016 | $2,514,000 | +413.1% | 2,230,000 | +446.6% | 0.01% | +366.7% |
| Q3 2016 | $490,000 | -71.4% | 408,000 | -72.4% | 0.00% | -70.0% |
| Q1 2016 | $1,715,000 | +1431.2% | 1,480,000 | +1620.9% | 0.01% | +900.0% |
| Q4 2015 | $112,000 | +111.3% | 86,000 | +109.8% | 0.00% | – |
| Q3 2015 | $53,000 | -99.6% | 41,000 | -99.5% | 0.00% | -100.0% |
| Q2 2015 | $12,260,000 | +249.9% | 7,955,000 | +237.8% | 0.06% | +215.0% |
| Q1 2015 | $3,504,000 | +2117.7% | 2,355,000 | +1657.5% | 0.02% | +1900.0% |
| Q4 2014 | $158,000 | -80.7% | 134,000 | -82.7% | 0.00% | -83.3% |
| Q3 2014 | $820,000 | -66.3% | 775,000 | -67.1% | 0.01% | -71.4% |
| Q2 2014 | $2,436,000 | – | 2,355,000 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ferox Capital Management LP | 6,000,000 | $6,271,000 | 4.60% |
| Weiss Asset Management LP | 27,058,000 | $28,040,000 | 2.16% |
| Birch Grove Capital LP | 4,643,000 | $4,802,000 | 1.91% |
| CSS LLC/IL | 20,256,000 | $20,993,000 | 0.89% |
| PIPER SANDLER & CO. | 1,000,000 | $1,036,000 | 0.86% |
| AQR Arbitrage LLC | 24,825,000 | $25,686,000 | 0.30% |
| CAPSTONE INVESTMENT ADVISORS, LLC | 17,000,000 | $17,589,000 | 0.20% |
| OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 5,000,000 | $5,182,000,000 | 0.12% |
| PALISADE CAPITAL MANAGEMENT, LP | 4,107,000 | $4,256,000 | 0.12% |
| Verition Fund Management LLC | 3,106,000 | $3,214,000 | 0.12% |